Pharmaceutical Technology, Sep 2, 2008 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Sep 2, 2008
Online Exclusive
A Catalyst for Environmental Consciousness
By Ram Murty
A recent book shows the links between synthesis, catalysis, and environmental protection.
The Potential of Continuous Sterile Manufacturing
By Patricia Van Arnum
Sterile manufacturing may be the next aspect of pharmaceutical manufacturing to consider in the continuous process paradigm.
Running a Marathon in Flip-Flops – Part 2: The Value of Incorporating Prerequisites into Equipment Qualification
By Jennifer Medlar , Nancy Cafmeyer
Equipment qualification is a critical step in ensuring that a product or service is provided accurately and consistently with regards to manufacturing and testing. The time-saving attribute of adding prerequisites to a qualification program, along with the benefit of gaining the ability to track and trend problem areas, make the addition both worthwhile and cost-effective.
Chiral Separations
By Patricia Van Arnum
The selection of the chiral stationary phase is an important consideration in separating enantiomers when using high-performance liquid chromatography, supercritical fluid chromatography, and simulated moving bed chromatography.
Special Report
Continuous Processing: Moving with or against the Manufacturing Flow
By Alexis Pellek , Patricia Van Arnum
Fueled by a need to reduce costs and improve efficiencies, continuous processing may be the next paradigm shift in pharmaceutical manufacturing.
Peer-Reviewed Research
Criticality Management of a Drug Product and its Manufacturing Process
By Filip Vanhoutte , Guy Smans , Luc Janssens , Marc Vanstockem
Criticality management combines pharmaceutical product, process, and material knowledge and risk management in one approach, which is reflected in a single document.
Dielectric Spectroscopy: Choosing the Right Approach
By A. Mathur , K. Sundara-Rajan , G. Rowe , A. V. Mamishev
This tutorial paper is meant to aid in dielectric-sensor selection
Ingredients Insider
Achieving Enantioselectivity
By Patricia Van Arnum
Carbon–hydrogen functionalization, ketone α-alkylation, and biocatalysis are some recent advances in asymmetric synthesis.
Outsourcing Outlook
Big Deals
By Jim Miller
Summer deals struck by Novartis and Lilly point to an evolution in contract services.
Washington Report
Drug Imports under Scrutiny
By Jill Wechsler
FDA is taking several measures to ensure that imported drugs meet manufacturing standards.
Packaging Forum
Sustainability Surprises
By Hallie Forcinio
Identifying the most sustainable packaging for a product is rarely a simple exercise.
Viewpoint
Global Warming Heats Up Need for Malaria Vaccine
By Sylvain Fleury
With economics and politics in the way, can we defeat the malaria epidemic before it defeats us?
From The Editor
Dirty Hands
By Michelle Hoffman
Are hypersanitation trends a result of scaremongering or a lack of faith in medicine?
Agent-In-Place
Hits and Strikes
By Control, a senior compliance officer
Operators are hit hard by breakage problems and strike out on FDA inspections.
PharmTech Talk
Make Yourself Count
By Maribel Rios
This year, the employment survey will acknowledge the industry's best employers.
News
Report From: India
By A. Nair
Differential pricing is making more than just an appearance in Asia's pharma market these days.
In the Spotlight
In the Spotlight
Editors' Picks of Pharmaceutical Science & Technology Innovations
Pharma Capsules
Pharma Capsules
Brief pharmaceutical news items for September 2008.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here